top of page

Publications

A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination

Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al

Cohort profile: Stop the Spread Ottawa (SSO)-a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination

Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, et al

Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens

Cholette F, Fabia R, Harris A, Ellis H, Cachero K, Schroeder L, et al

Between April and August 2022, 98% of Canadians had antibodies against COVID-19 and 54% had antibodies from a previous infection

Statistics Canada

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections

Unninayar D, Falcone EL, Chapdelaine H, Vinh DC, Top KA, Derfalvi B, et al.

Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years

Tsampalieros A, Zemek R, Barrowman N, Langlois MA, Arnold C, McGahern C, et al

Infection Rate and Risk Factors of SARS-CoV-2 Infection in Retail Workers at the Onset of the COVID-19 Pandemic, Quebec, Canada

Santerre K, Theriault M, Brousseau N, Langlois MA, Arnold C, Pelletier JN, et al.

The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study

Almeida ND, Schiller I, Ke D, Sakr E, Plesa M, Vanamala S, et al

Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination

Cuperlovic-Culf M, Bennett SAL, Galipeau Y, McCluskie PS, Arnold C, Bagheri S, et al.

Clinical and serological predictors of post COVID-19 condition-findings from a Canadian prospective cohort study

Collins E, Galipeau Y, Arnold C, Bhereur A, Booth R, Buchan AC, et al.

COVID-19: Longer-term symptoms among Canadian adults - Fourth Report

Statistics Canada

Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study

Costiniuk CT, Lee T, Singer J, Galipeau Y, Arnold C, Langlois MA, et al

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity

D'Souza M, Keeshan A, Gravel CA, Langlois MA, Cooper CL.

COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies

Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, et al.

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Bhella SD, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, et al.

Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5

Sakr E, Almeida ND, Langlois MA, Dasgupta K, Mazer BD

Prevalence of SARS-CoV-2 infection among obstetric patients in Ottawa, Canada: a descriptive study

Fakhraei R, Erwin E, Alibhai KM, Murphy MSQ, Dingwall-Harvey ALJ, White RR, et al

Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals

Whelan M, Galipeau Y, White-Al Habeeb N, Konforte D, Abou El Hassan M, Booth RA, et al

Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination

Keeshan A, Galipeau Y, Heiskanen A, Collins E, McCluskie PS, Arnold C, et al

Cohort profile: investigating SARS-CoV-2 infection and the health and psychosocial impact of the COVID-19 pandemic in the Canadian CHILD Cohort

Azeez R, Lotoski L, Dubeau A, Rodriguez N, Reyna ME, Freitas T, et al

Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Costiniuk CT, Singer J, Lee T, Galipeau Y, McCluskie PS, Arnold C, et al

Experiences of Canadians with long-term symptoms following COVID-19

Statistics Canada - Kuang S, Earl S, Clarke J, Zakaria D, Demers A, Aziz S.

Continuous false positive results by SARS-CoV-2 rapid antigen testing: a case report

Galipeau Y, Xavier A, Dyks A, Cooper C, Langlois MA

COVID-19 vaccine immunogenicity in people with HIV

Costiniuk CT, Singer J, Lee T, Langlois MA, Arnold C, Galipeau Y, et al

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series

Colmegna I, Valerio V, Amiable N, Useche M, Rampakakis E, Flamand L, et al.

Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study

Bhatt M, Plint AC, Tang K, Malley R, Huy AP, McGahern C, et al

Self-reported COVID-19 test results in Canada, January 2020 to March 2022

Statistics Canada

Antibody Seronegativity in COVID-19 RT-PCR-Positive Children

Bhatt M, Zemek RL, Tang K, Malley R, Plint AC, Pham-Huy A, et al

Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study

Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, et al

Seropositivity and risk factors for SARS-CoV-2 infection in a South Asian community in Ontario: a cross-sectional analysis of a prospective cohort study

Anand SS, Arnold C, Bangdiwala SI, Bolotin S, Bowdish D, Chanchlani R, et al

Long-term symptoms in Canadian adults who tested positive for COVID-19 or suspected an infection, January 2020 to August 2022

Statistics Canada

CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study

Costiniuk CT, Singer J, Langlois M-A, Kulic I, Needham J, Burchell A, et al.

Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison

Cholette F, Mesa C, Harris A, Ellis H, Cachero K, Lacap P, et al.

Few Canadians had antibodies against SARS-CoV-2 in early 2021

Statistics Canada

© 2024 Serology and Diagnostics High Throughput Facility

bottom of page